ClinicalTrials.gg
RecruitingNCT07019558AO-SCAUpdated Nov 20, 2025

Ophthalmological Disorders in Dominant Spinal-cerebellar Ataxias

An interventional study of Neurological assessment and Ophthalmological assessment in Spinocerebellar Ataxia, sponsored by University Hospital, Montpellier. Recruiting at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by University Hospital, Montpellier · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Spinocerebellar Ataxias with a site in France — 5 open to participants now, 7 under way, none of them phase 3. Spinocerebellar Ataxias · France.

Started
2025
with 1 other
No phase
3 of 13
2 open now
Registered
12th of 13
by date
Lead sponsor
2 of 13
University Hospital, Montpellier

Among the 13 studies in Spinocerebellar Ataxias with a site in France, this one is one of 2 that started in 2025, is one of 3 with no phase, and was the 12th registered.

Spinocerebellar Ataxias

95 studies on the registry are indexed under Spinocerebellar Ataxias; 25 are open to participants now.

Browse Spinocerebellar Ataxias studies →

Open to participants now

5 of the 13 studies in Spinocerebellar Ataxias with a site in France are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 16 Spinocerebellar Ataxias studies recruiting now, 8 (50%) set no upper age limit and 3 (19%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Spinocerebellar Ataxias with a site in France, or all of them as a file.
02

Study summary

Spinocerebellar ataxias (SCA) are rare genetic neurological disorders. The most common forms are SCA1, SCA2 and SCA3. Another more recently identified cause of ataxia is SCA27B.

These are progressive, incapacitating pathologies, with adult onset (generally between 30 and 60 years of age) and progressive involvement. They are characterized by gait instability (ataxia), coordination disorders (dysmetria) and speech disorders (dysarthria). A complex disorder may also be present, with impaired ocular motility, double vision (diplopia) and difficulties with eye movements (ophthalmoplegia).

In clinical practice, investigators have observed patients with advanced forms of SCA1 or SCA3 reporting a progressive decline in visual acuity. Other recent scientific observations confirm the possible presence of additional ophthalmological damage to the retina or optic nerve in SCA1, SCA2 and SCA3 pathologies.

This study is a cross-sectional study, including subjects with SCA1, SCA2 and SCA3 at different stages of the disease, including the presymptomatic stage, with a complete and systematic study of visual damage.

The same study will be applied to subjects with SCA27B in order to study the presence or absence of visual impairment, and possibly compare it with those of patients with polyglutamine-expanded SCA.

03

Conditions studied

  • Spinocerebellar Ataxia

Keywords

  • spinocerebellar ataxias
  • ophtalmology
  • neurology
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 80,
  • Presence of pathological expansion in ATXN1 (> or equal to 39 CAG), ATXN2 (> or equal to 33 CAG) or ATXN3 (> or equal to 45 CAG) genes, responsible respectively for SCA1, SCA2 or SCA3 or a pathological expansion (>250 GAA) in the FGF14 gene responsible for SCA27B pathology,
  • Sujet symptomatic (SARA greater than or equal to 4) or presymptomatic (SARA \< 4).

Exclusion criteria

Exclusion Criteria:

  • Study-specific criteria:

    • Subjects with systemic or ophthalmological disease that could affect the retina, impair fundus examination (severe cataract, severe/decompensated diabetes), or cause visual acuity below 20/40, intraocular pressure > 20 mmHg, "cup to disc" ratio > 0. 5, or severe refractive errors
    • Subjects with extremely severe neurological impairment, with a significant impact on the ability to perform most ophthalmological examinations; for example in patients for whom sitting, even with back support and cannot be maintained. The possibility of including subjects with a severe form will be evaluated on a case-by-case basis, according to the opinion of the principal investigator and the ophthalmologist.
  • General exclusion criteria relating to regulations:

    • Failure to obtain consent (adults, non-emancipated minors, persons not in a position to give consent, research carried out in emergency situations, etc.),
    • Participants who have reached the maximum amount of compensation for their participation inresearch,
    • Non-affiliation with a social security scheme,
    • Persons placed under court protection,
    • Person taking part in research.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Participants

    * Symptomatic subjects with SCA1, SCA2 or SCA3, symptomatic subjects with SCA27B. * Presymptomatic subjects carrying the mutation for SCA1, SCA2 and SCA3.

    Other: Neurological assessment · Diagnostic Test: Ophthalmological assessment

Interventions

  • OtherNeurological assessment

    Collect retrospective and current clinical data and assess motor impairment

  • Diagnostic testOphthalmological assessment

    Ophthalmological assessment of possible optic nerve or retinal damage.

06

What researchers measure

Primary outcomes

  1. Percentage (%) of patients with SCA1, SCA2, or SCA3 showing abnormalities for each ophthalmological examination performed.

    * Visual Acuity Assessment: Significant reduction in visual acuity (\<5/10) unexplained by other causes (such as age or other diseases). * Color Vision: Normal or pathological, with description of the axis * Fundus Examination: Normal or pathological (presence of retinopathy or optic nerve atrophy). * Optical Coherence Tomography (OCT): Evaluation of retinal nerve fiber layer (RNFL) and macular thickness (at 3 mm and 6 mm from the center), including retinal thickness, ganglion cell layer thickness, and the status of the ellipsoid zone. These thickness measurements are quantified according to age-adjusted normative database values. * Visual Evoked Potentials (VEP): Normal or pathological; if pathological, characterized by prolonged conduction times and/or reduced amplitude. * Electroretinogram (ERG): Normal or pathological; if pathological, defined by alteration (\>2 standard deviations) in the amplitude or latency of a- or b-waves under photopic or scotopic conditions

    Time frame: 1 day

Secondary outcomes

  1. Percentage (%) of subjects showing abnormalities for each ophthalmological examination performed

    Percentage (%) of subjects showing abnormalities for each ophthalmological examination performed to compare disorder across the three different types of SCA.

    Time frame: 1 day

  2. Severity of clinical impairment assessed by the SARA score (Scale for the Assessment and Rating of Ataxia) and the associated disability scale.

    Severity of clinical impairment assessed by the SARA score (Scale for the Assessment and Rating of Ataxia) and the associated disability scale to correlate ophthalmological abnormalities. The SARA is a tool for assessing ataxia. It has eight categories with accumulative score ranging from 0 (no ataxia) to 40 (most severe ataxia) where higher scores indicate worse clinical impairment.

    Time frame: 1 day

  3. Disease duration: number of years between the estimated symptom onset and the time of study inclusion.

    Disease duration: number of years between the estimated symptom onset and the time of study inclusion to assess whether this disorder is early and already present at a presymptomatic stage

    Time frame: Day 1

Other outcomes

  1. Percentage (%) of patients with SCA27B showing abnormalities for each ophthalmological examination performed.

    * Visual Acuity Assessment: Significant reduction in visual acuity (\<5/10) unexplained by other causes (such as age or other diseases). * Color Vision: Normal or pathological, with description of the axis * Fundus Examination: Normal or pathological (presence of retinopathy or optic nerve atrophy). * Optical Coherence Tomography (OCT): Evaluation of retinal nerve fiber layer (RNFL) and macular thickness (at 3 mm and 6 mm from the center), including retinal thickness, ganglion cell layer thickness, and the status of the ellipsoid zone. These thickness measurements are quantified according to age-adjusted normative database values. * Visual Evoked Potentials (VEP): Normal or pathological; if pathological, characterized by prolonged conduction times and/or reduced amplitude. * Electroretinogram (ERG): Normal or pathological; if pathological, defined by alteration (\>2 standard deviations) in the amplitude or latency of a- or b-waves under photopic or scotopic conditions

    Time frame: 1 day

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2027, 24 months after the start.

Of 28 interventional studies with no phase under Spinocerebellar Ataxias, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 24 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2025
First posted
Jun 13, 2025
StartActual
Oct 10, 2025
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07019558
Responsible party
Sponsor
First posted
Jun 13, 2025
Start date
Oct 10, 2025
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Nov 20, 2025

Study contacts

Cecilia Marelli, PH
Contact
c-marelli@chu-montpellier.fr
+33(0)467337413

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion